Moxonidine

Centrally acting antihypertensive, imidazoline I1 receptor agonist

ATC code: C02AC05

Updated 23 Sep 2026 · Methodology

Indications

Hypertension

Third line

Moxonidine is a centrally acting antihypertensive. The AEMPS Moxon label gives it one indication: treatment of arterial hypertension. It lowers blood pressure reliably, but moxonidine has no large outcome trials covering myocardial infarction, stroke or death, so the 2024 hypertension guideline places centrally acting sympatholytics behind the five main classes: ACE inhibitors, ARBs, calcium channel blockers, thiazide-like diuretics and beta blockers. Its practical niche sits elsewhere – once the main classes are exhausted or poorly tolerated. Titration starts at 0.2 mg daily, with a lower ceiling once renal filtration falls below 60 ml/min. Withdrawal takes two weeks rather than one day, and when a beta blocker runs alongside, the beta blocker goes first.

Sources

ICD-10: I10 · ICD-11: BA00

Resistant arterial hypertension

Adjunct

In resistant hypertension, where blood pressure stays above target on three drugs including a diuretic, a fourth is added. The 2024 guideline names spironolactone first for that slot and leaves centrally acting sympatholytics for cases where spironolactone did not work out because of hyperkalaemia, gynaecomastia or low renal filtration. Moxonidine does the job there, but its evidence base is a drop in blood pressure numbers rather than a drop in strokes. A practical point when a fourth drug goes in: moxonidine adds to any other antihypertensive by mechanism, and the first days after starting bring orthostatic hypotension, especially in older people. Standing blood pressure is measured separately from seated blood pressure.

Sources

ICD-10: I10 · ICD-11: BA00

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

Hypertensive urgency

Not recommended

Moxonidine often sits in the home cabinet as a sublingual rescue tablet for a blood pressure spike, copying the way captopril is used. The AEMPS Moxon label describes no such use: it covers scheduled treatment of arterial hypertension with slow titration. There are no clinical studies comparing moxonidine with placebo or with another drug during an acute rise in blood pressure. The 2024 guideline does not call for emergency lowering when a rise comes without organ damage: a fast drop is more dangerous than the numbers, because the brain and kidneys lose perfusion. A separate trap is the sublingual route: the moxonidine tablet is film-coated and built for intestinal absorption, so under the tongue the delivered dose becomes unpredictable. If moxonidine was prescribed as emergency rescue for a hypertensive spike, consider seeking a second opinion.

Sources

ICD-10: I16.0 · ICD-11: BA03

Heart failure

Not recommended

Treating heart failure by damping sympathetic drive looked logical: noradrenaline runs high when ejection fraction is low, and lowering it promised benefit. The MOXCON trial (Eur J Heart Fail 2003) tested that directly in 1934 patients and stopped early: 54 people died on sustained-release moxonidine against 32 on placebo, with more hospital admissions and more myocardial infarctions as well. Since then moxonidine has no place in heart failure regimens. The AEMPS Moxon label goes further and lists heart failure among the contraindications, alongside bradycardia below 50 beats per minute, sick sinus syndrome and second or third degree AV block. If moxonidine was suggested for the heart in reduced ejection fraction, consider seeking a second opinion.

Sources

ICD-10: I50 · ICD-11: BD10

How to read tiers A–F

AStrong evidence – first or second line in international guidelines
BRecommended in selected cases
CStudy data contradict each other
DBenefit not proven, no documented harm
FDocumented harm, or risk without benefit

Mechanism of action

Moxonidine binds imidazoline I1 receptors in the rostral ventrolateral medulla and damps sympathetic outflow to vessels, heart and kidneys. Peripheral resistance falls and blood pressure drops without a marked rise in heart rate. Its affinity for alpha-2 adrenoceptors is roughly 30 times lower than for I1, which is why dry mouth and sedation are milder than with clonidine. It leaves the body through the kidneys largely unchanged, so the dose is capped once glomerular filtration falls below 60 ml/min. Abrupt withdrawal is unwanted: the AEMPS label asks for a gradual taper over about two weeks.

Safety

Contraindications

Hypersensitivity to moxonidine or to any excipient
Sick sinus syndrome
Resting bradycardia below 50 beats per minute
Second and third degree AV block
Heart failure

Serious adverse effects

Marked hypotension with syncope, especially combined with other antihypertensives
Bradycardia and AV conduction disturbance
Rebound rise in blood pressure after abrupt withdrawal
Angioedema

Common adverse effects

Dry mouth
Headache
Somnolence and fatigue
Dizziness, including on standing up

Pregnancy: can you take Moxonidine?

Data on moxonidine in pregnancy are limited and the AEMPS label advises against its use during pregnancy. When pregnancy is planned or confirmed, the drug is switched to an agent with a studied profile: methyldopa, labetalol or extended-release nifedipine.

Breastfeeding: can you take Moxonidine?

Moxonidine passes into breast milk, so it is not used while breastfeeding. When treatment is needed, a drug with known lactation data is chosen rather than continuing moxonidine with feeding interrupted.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Label mentions5 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

Majorantidepresivos tricíclicosclass named in the label
«Debido a que los antidepresivos tricíclicos pueden reducir la eficacia de los fármacos antihipertensivos de acción central, no se recomienda la administración conjunta de los antidepresivos…»
AEMPS, section 4.5 · Open on CIMA
benzodiazepinasclass named in the label
«En sujetos tratados con loracepam, la moxonidina aumentó moderadamente el deterioro de las funciones cognitivas. La moxonidina puede aumentar el efecto sedante de las benzodiazepinas cuando se…»
AEMPS, section 4.5 · Open on CIMA
depresores del SNCclass named in the label
«La moxonidina puede potenciar el efecto sedante de los antidepresivos tricíclicos (evitar la prescripción conjunta), de los tranquilizantes, el alcohol, los sedantes y los hipnóticos.»
AEMPS, section 4.5 · Open on CIMA

From other drugs’ labels

MajorNebivolol
«Antihipertensivos de acción central (clonidina, guanfacina, moxonidina, metildopa, rilmenidina): el uso concomitante de antihipertensivos de acción central puede empeorar la insuficiencia cardiaca a…»
AEMPS, section 4.5 · Open on CIMA
Propranolol
«Combinación no recomendada: Antihipertensivos de acción central (clonidina, moxonidina, metildopa):»
AEMPS, section 4.5 · Open on CIMA

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Moxonidine used for?

Moxonidine is evaluated for the following indications with varying evidence strength: Hypertension (evidence tier B), Resistant arterial hypertension (evidence tier C), Hypertensive urgency (evidence tier D). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Moxonidine?

Common side effects of Moxonidine (≥ 1 in 100): Dry mouth, Headache, Somnolence and fatigue, Dizziness, including on standing up. See the Safety section for uncommon and serious reactions.

Is Moxonidine safe during pregnancy?

Is Moxonidine compatible with breastfeeding?

Who should not take Moxonidine?

Moxonidine is contraindicated in: Hypersensitivity to moxonidine or to any excipient; Sick sinus syndrome; Resting bradycardia below 50 beats per minute; Second and third degree AV block; Heart failure. Full list in the Safety section.

Official sources

Direct links to regulator labels. Open in a new tab.

AEMPS / CIMALabel dated 07/11/2024

Other drugs in this group

Clonidine, Doxazosin, Hydralazine, Methyldopa, Riociguat